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Abstract
Background: Fibrotic interstitial lung diseases (ILDs) are chronic and often progressive conditions resulting in
substantial morbidity and mortality. Shortness of breath, a symptom often linked to oxygen desaturation on
exertion, is tightly linked to worsening quality of life in these patients. Although ambulatory oxygen is used
empirically in their treatment, there are no ILD-specific guidelines on its use. To our knowledge, no studies are
available on the effects of ambulatory oxygen on day-to-day life in patients with ILD.
Methods/design: Ambulatory oxygen in fibrotic lung disease (AmbOx) is a multicentre, randomised controlled
crossover trial (RCT) funded by the Research for Patient Benefit Programme of the National Institute for Health
Research. The trial will compare ambulatory oxygen used during daily activities with no ambulatory oxygen in
patients with fibrotic lung disease whose oxygen saturation (SaO2) is ≥94% at rest, but drops to ≤88% on a
6-min Walk Test. The randomised controlled trial (RCT) will evaluate the effects on health status (measured by
the King’s Brief ILD Questionnaire: K-BILD) of ambulatory oxygen used at home, at an optimal flow rate
determined by titration at screening visit, and administered for a 2-week period, compared to 2 weeks off
oxygen. Key secondary outcomes will include breathlessness on activity scores, as measured by the University
of California San Diego Shortness of Breath Questionnaire, global patient assessment of change scores, as well as
quality of life scores (St George’s Respiratory Questionnaire), anxiety and depression scores (Hospital Anxiety
and Depression Scale), activity markers measured by SenseWear Armbands, pulse oximetry measurements,
patient-reported daily activities, patient- and oxygen company-reported oxygen cylinder use. The study also
includes a qualitative component and will explore in interviews patients’ experiences of the use of a portable
oxygen supply and trial participation in a subgroup of 20 patients and carers.
Discussion: This is the first RCT of the effects of ambulatory oxygen during daily life on health status and
breathlessness in fibrotic lung disease. The results generated should provide the basis for setting up ILD-specific
guidelines for the use of ambulatory oxygen.
Trial registration: National Clinical Trials Registry, identifier: NCT02286063. Registered on 8 October 2014
(retrospectively registered).
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Background
The hallmark symptom of fibrotic interstitial lung dis-
eases (ILD) is breathlessness, which progressively limits
the ability of patients to carry out routine activities and
ultimately can affect their independence. Breathlessness
is the main determinant of quality of life in patients with
idiopathic pulmonary fibrosis (IPF), the most common
of the idiopathic ILDs [1]. Fibrotic lung diseases pro-
foundly affect an individual’s sense of wellbeing, with
anxiety, depression and fatigue often accompanying ex-
ertional limitation, leading to a loss of health status.
With limited pharmacological therapy proven to prolong
survival in many ILDs, attempts to improve or maintain
health status are of crucial importance.
Breathlessness on exertion, formally measured by the
6-min Walk Test (6MWT) [2], is often associated with a
fall in oxygen saturation (SaO2), which in ILD patients
can be particularly marked [3–6]. The 6MWT is a
widely used field test measuring functional exercise cap-
acity, repeatedly observed to have good validity as a
functional and prognostic marker in IPF [7, 8]. Ambula-
tory oxygen used during a 6MWT or bicycle endurance
test has been reported to improve breathlessness, dis-
tance walked, and breathlessness recovery time [9, 10].
Frank and coauthors reported that further up-titration
of ambulatory oxygen in order to maintain saturation
values above 90% and/or reaching a 6-L/min flow rate
during a 6MWT seemed to improve exercise capacity in
IPF, as measured by a 6MWT, even in patients already
using oxygen at home [11]. However, two studies have
failed to report a significant benefit on distance walked
or dyspnoea of supplemental oxygen on either the
6MWT [12] or a shuttle endurance test [13], possibly
because neither adequately titrated oxygen requirements
to appropriately correct the patient’s exertional desatur-
ation, as suggested in a recent Cochrane review [14].
Although a number of chest physicians prescribe ambu-
latory oxygen to ILD patients with desaturation on exer-
cise, there are no nationally recognised guidelines to
direct ambulatory oxygen prescription. In particular, NICE
guidelines for oxygen use only address chronic obstructive
pulmonary disease (COPD): (http://guidance.nice.org.uk/
CG101), a disease which markedly differs from IPF or
other ILDs. The recent British Thoracic Society (BTS)
oxygen guidelines only briefly touch on ambulatory
oxygen and give no specific guidance on its use in ILD,
indeed recommending against its use in most cases
[15]. Specifically, there are no published studies investi-
gating the effects of ambulatory oxygen on day-to-day
life in patients with fibrotic ILD, or assessing whether
oxygen-induced improvements in 6MWT performance
predict response to supplemental oxygen during activ-
ities of daily living, and an overall improvement in
health status.
We have, therefore, planned a prospective study to as-
sess whether individuals with fibrotic ILD whose SaO2
falls to ≤88% on a 6MWT, but are not hypoxic at rest,
benefit from the use of ambulatory oxygen in their daily
lives, by assessing changes in health status. The pro-
posed project is the first of its kind in ILD, and ad-
dresses an under-researched area in urgent need of
study. The study has the potential to lead to significant
advances in the treatment and the understanding of ex-
ercise limitation in patients with ILD, and will represent
an essential step towards the development of guidelines
on oxygen use in ILD.
Objectives
The main aim of this project is to establish whether am-
bulatory oxygen in patients with fibrotic ILD whose oxy-
gen saturation falls to ≤88% on a 6MWT, leads to a
significant improvement in health status, as measured by
the King’s Brief Interstitial Lung Disease Questionnaire
(K-BILD) [16]. Key additional outcomes will be the
evaluation of dyspnoea during activities of daily living as
measured by the University of California San Diego
Shortness of Breath Questionnaire (UCSD SOBQ) [17],
as well as the global patient assessment of change [18].
Further secondary outcomes will include monitored
(SenseWear Armbands) and patient-recorded activity
parameters, as well as quality of life scores assessed by
the St. George’s Respiratory Questionnaire (SGRQ) [19]
and the Hospital Anxiety and Depression Scale (HADS)
[20]. We also aim to assess whether the improvement in
6MWT performance induced by portable oxygen can
predict benefit of ambulatory oxygen in day-to-day liv-
ing, by a placebo air-controlled 6MWT performed at the
start of the study, to assess changes to the 6MWT pa-
rameters induced by supplemental oxygen. An economic
evaluation will assess the potential value for money pro-
vided by ambulatory oxygen by comparing the health
system costs and health-related benefits to those of no
ambulatory oxygen.
In addition, qualitative semistructured interviews at
the end of the 4-week period in a subgroup of 20 pa-
tients will be conducted to evaluate patients’ and carers’
experiences regarding the use of ambulatory oxygen and
trial participation.
Methods/design
The AmbOx study is a UK, multicentre, prospective,
randomised controlled crossover trial of ambulatory
oxygen against no ambulatory oxygen over a 4-week
period (2 weeks on ambulatory oxygen and 2 weeks on
no portable oxygen), to evaluate the effects of ambula-
tory oxygen on health status in patients with ILD. Pa-
tients whose SaO2 at rest is ≥94% will be screened by
performing a 6MWT as part of their routine clinical
Visca et al. Trials  (2017) 18:201 Page 2 of 11
assessment in order to identify those patients whose
SaO2 drops to ≤88%. In those who desaturate below
this threshold, a further 6MWT will be conducted
with titration of oxygen flow so that for least half of
the 6MWT, oxygen saturation with supplemental oxy-
gen is maintained at >90% (for more detailed informa-
tion on oxygen titration, see section 10.2 of the
protocol (Additional file 1).
Following consent to the study, patients meeting eligi-
bility criteria and deemed clinically stable at the end of
the 2-week run-in period, and not expecting to require
any change in their background medication, will be
assigned in random order to 2 weeks on ambulatory
oxygen or no oxygen during the baseline visit. Optimal
oxygen flow rates will be determined during the screen-
ing visit on the basis of the entry 6MWT on oxygen, as
detailed above. At the start of the active part of the trial,
the effects of ambulatory oxygen on 6MWT perform-
ance will be formally evaluated by performing two
6MWTs, one on oxygen and one on placebo air-filled
canisters, at the flow rate identified during the screening
visit, in random order, with a rest of at least 30 min be-
tween tests. The patient will be blind to the content of
the canisters. Measured parameters will include 6MWT
distance, oxygen saturation and heart rate measured
continuously (WristOx2™ model 3150), Borg Dyspnoea
and Fatigue Score [21] before and at the end of the test,
time to recovery of heart rate, and oxygen saturation.
These parameters will be related to changes in the pri-
mary and secondary outcome variables as detailed in
subsequent sections, to identify any baseline predictors
of responsiveness. Two different randomisation lists, in-
dependent of each other, will, therefore, be used. One
randomisation list will determine the order of placebo
air versus oxygen-filled canisters for the placebo-
controlled 6MWT occurring at the baseline visit, the
other randomisation list will determine the order of oxy-
gen versus no intervention for the 4-week trial.
Following completion of the 2 weeks on the treat-
ment arm assigned during the baseline visit (ambula-
tory oxygen or no intervention), patients will cross
over to receive the alternative treatment for a further
2 weeks. The study design is outlined in Additional
file 2: Figure S1. More details are available in the
AmbOx protocol, version 3.0, dated 1 December
2014 (Additional file 1).
Location and setting
AmbOx is sponsored by the Royal Brompton and Hare-
field NHS Foundation Trust and will recruit subjects
from three UK centres (RBH; Aintree University Hos-
pital led by LGS; Bristol ILD Unit led by HA), all with
expertise in ILD.
Study population and eligibility criteria
A total of 80 subjects will be enrolled and randomised.
Subjects should fulfil the following criteria:
 A diagnosis of fibrotic lung disease, including
idiopathic pulmonary fibrosis, fibrotic nonspecific
interstitial pneumonia, fibrotic hypersensitivity
pneumonitis, fibrotic organising pneumonia and
nonclassifiable fibrotic ILD. Patients with fibrotic
sarcoidosis or connective tissue disease (CTD)-
associated fibrotic ILD will be included provided
that there is no significant musculoskeletal
involvement
 Patients whose oxygen saturation (SaO2) at rest
on room air is ≥94% and falls to ≤88% on a
baseline 6MWT
 Patients with stable symptoms (no changes in
medications and no chest infections) and
treatment during the period of 4 weeks prior to
being randomised into the study, including the
2-week run-in period
 Patients able to provide written informed consent
The Patient Information Sheet and Informed Consent
Form can be found in Additional files 3 and 4, respect-
ively. Subjects should not enter the study if any of the
exclusion criteria listed in Additional file 5 are present.
Patient will have had an echocardiogram and spirometry
performed within 6 months prior to the screening visit
or within 6 weeks following this. Serum brain natriuretic
peptide (BNP) levels will be collected for all patients
within a month from the screening visit.
Intervention
Light-weight oxygen gas cylinders will be used to pro-
vide oxygen during activities (ambulatory oxygen). Am-
bulatory oxygen will be provided by the relevant oxygen
companies in the UK, through submission of a Home
Oxygen Order Form (HOOF) based on the location of
the patient participating in the study. Overall, there are
four oxygen companies which provide supplemental
oxygen in the UK, including Air Liquide (which services
North and South London, North and South West
England, and the East Midlands), BOC (Eastern England
and NorthEast), Baywater Healthcare (Yorkshire and
Humberside, West Midlands and Wales) and Dolby
Vivisol (South Central England and South East Coast).
Continuous oxygen flow via nasal cannulae will be used
for all patients to standardise mode of delivery. Oxygen
flow rates will be determined on the basis of the entry
6MWT on oxygen, so as to maintain oxygen saturation
of ≥90% for at least half of the 6MWT, where possible. If
the patients are randomised to start on oxygen on the
first 2 weeks of the 4-week trial period, the company will
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be asked to remove any unused oxygen cylinders on the
day of the crossover to the 2 weeks ‘off ’ oxygen. To de-
termine oxygen use during the 2 weeks when patients
are randomised to be on treatment, patients will be
asked to keep a daily diary recording the number of
hours spent using oxygen. Investigators will also ask the
relevant oxygen company to provide the number of cyl-
inders delivered to the patient per week along with the
number of any unused or partially used cylinders
(approximating to the nearest 25%) at the end of the
2 weeks on oxygen, wherever possible. To further valid-
ate patient-reported use of oxygen cylinders, a re-
searcher at the Aintree site will sample 10 consecutive
patients living in the nearby area and will visit patients
at home at the end of the 2 weeks of ambulatory oxygen
to independently assess numbers of fully used, half-used
and full oxygen cylinders. Comparison between patient-
and researcher-reported cylinders use will be included in
data analysis. More information is provided in Section
13 of the study protocol.
The study design does not include a placebo arm
because:
 The intervention is a combination of possible
benefits from oxygen and the disadvantage of
canister weight. These cannot be separated. Placebo
control is impossible because there is no means of
providing placebo weight. Attempts to control solely
for oxygen use without taking canister weight into
account would not be clinically meaningful. In a
recent COPD study, cylinder weight was reported
as a barrier to use by 93% of study participants [22]
 A positive result against an air-filled canister arm
would be clinically uninterpretable. This is a study
design in which the ‘placebo’ would be actively
harmful to study participants. Carriage of an
air-filled cylinder would be expected to lead to
earlier desaturation and reduced exercise tolerance.
Such a design would not inform the real-life
comparison between oxygen plus cylinder and no
intervention
 It should also be stressed that objective measures
of change will be evaluated as secondary endpoints:
we expect to explore correlations between these
variables and the primary endpoint to exclude the
possibility that an observed treatment benefit on
the primary endpoint might be confounded by a
placebo effect
Concomitant medication
It will be possible to introduce any rescue medication
during the study period as judged appropriate by the
treating physician. However, the aim is to enrol subjects
whose treatment is not expected to change during the
4-week treatment period of the trial. Patients who are on
established treatment for their ILD, with immunosuppres-
sants, corticosteroids, N-Acetyl Cysteine (NAC) and/or
antifibrotic agents, will continue on their regular medica-
tion. Concomitant medication will be recorded in patient’s
notes and the Case Report Forms (CRFs).
Outcomes
Primary outcome measure
 Difference in the health status measured by the
K-BILD (global score and its three domains) [16]
between the two treatment arms (ambulatory
oxygen versus no oxygen) at the end of the relevant
treatment period
Key secondary outcome measures
 Difference in the UCSD Shortness of Breath
Questionnaire at the end of each treatment period
(oxygen versus no oxygen) [17]
 Difference in global patient assessment scores [18]
Additional secondary outcome measures
 Difference in health-related quality of life scores
(SGRQ, HDAS) [19]
 Difference in activity parameter scores
(SenseWear Armbands)
 Difference in patient-reported activity levels as per
patient daily diaries
 Difference in the 48-h oxygen saturation scores
recorded by portable oximeters (to be also used as
an indirect measure of compliance)
 Difference in the 48-h oximeter recorded heart rate
 Analyses on the placebo-controlled 6MWT on oxygen
versus placebo air cylinders to assess whether the
response to oxygen on the 6MWT predicts benefit
of ambulatory oxygen in day-to-day life
 Oxygen cylinder use
 Safety and tolerability
Explanatory outcome measures
 Benefit of ambulatory oxygen in relation to the
following:
o Improvement in baseline 6MWT performance
on oxygen (at the flow determined during the
screening visit) compared to placebo air
o Outcome in relation to underlying ILD
diagnosis: IPF versus non-IPF
o Outcome in relation to the presence of
pulmonary vascular disease/pulmonary
hypertension (PH), defined on the basis of
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baseline echocardiogram (right ventricular
systolic pressure (RVSP) >40 mmHg and/or right
ventricular (RV) dilatation/reduced function)
and/or elevated baseline serum BNP levels
Qualitative interviews
The use of semistructured interviews in a subset of patients
at the end of the study is aimed at identifying patient-
derived expectations and concerns over the psychological
and practical barriers faced when using ambulatory oxygen.
Participant timeline
The time schedule for the enrolment, interventions and
assessments for participants is shown in Additional file
2: Figure S1 and in Fig. 1. An indexed Standard Protocol
Items: Recommendations for Interventional Trials (SPIRIT)
Checklist can be found in Additional file 6.
Assignment of interventions
Randomisation allocation as to the order of treatment
will be released using an interactive web-based random-
isation system (InForm), set up by Imperial College
Clinical Trials Unit (ICTU). Simple, block-method ran-
domisation will be performed to determine the order of
treatment.
All study patients will be randomised during baseline visit
as follows:
 Randomisation as to the order in which subjects
will perform the 6MWT on oxygen versus air.
The patients will be blind to the content of the
canisters
 Randomisation as to the order in which subjects
will have the portable home oxygen versus no
oxygen during the first 2 weeks of treatment
Fig. 1 SPIRIT Schedule of Events
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Sample size estimate
As stated above, the primary outcome measure is the differ-
ence between the health status score measured by the K-
BILD collected after 2 weeks on ambulatory oxygen and the
K-BILD collected after 2 weeks on no oxygen. The repeatabil-
ity of the K-BILD at 2 weeks in patients with stable ILD is
high, with an intraclass coefficient for domains and total score
of 0.86–0.94 [16]. This study is powered to detect a difference
of 8 units in the K-BILD total score, the minimally clinically
important difference (SD, 20), recently estimated [23].
We calculated that a sample size of 80 randomised
patients would allow 90% power at 5% significance to
detect a difference of at least 8 points between the two
crossover trial arms, allowing for a 15% dropout rate, in
view of the high morbidity/mortality of the disease. This de-
gree of power will also allow us to perform some explana-
tory subgroup analyses, as out lined above. Although the
study is powered to allow a 15% dropout rate, we will make
every effort to minimise patient loss and missing data dur-
ing the trial period [24]. In order to maximise completeness
of data, patients will be called at the end of each week
during the trial period. They will be reminded to wear the
activity monitor and/or the oximeter for the allocated time,
and will be encouraged to continue filling in their daily
activity diaries. The software used for power calculations
was ‘PS Power and Sample Size calculator version 3.0 by
William Dupont and Walton Plummer 2009’. For the
qualitative component, it is anticipated that a subsample of
N = 20 will be adequate to achieve theoretical saturation.
Data collection and management
Quality of life/Shortness of Breath Questionnaire data
The primary outcome measurement will be the difference in
K-BILD scores on completion of the 2 weeks on ambulatory
oxygen compared to no oxygen. All questionnaires will be
self-administered during the study visits, and will be com-
pleted at baseline and repeated at the follow-up crossover
visit after 2 weeks since the baseline visit and at the final
follow-up visit at 4 weeks. In addition to the K-BILD, patients
will be asked to complete the UCSD SOBQ [17], a widely
validated index, designed to assess activity-related dyspnoea,
as well as the global patient assessment of change [18], the
SGRQ [19] and the HADS, both validated in ILD [20].
Activity assessment
During the second week of each of the 2-week periods of
the study treatment, patients will be asked to wear an
activity monitor during waking hours, the SenseWear
Armband (Bodymedia – Pittsburgh, PA, USA), which
measures energy expenditure, daily number of steps, and
time spent at different levels of physical activity.
SenseWear-derived measurements are sensitive and re-
peatable in patients with chronic lung disease [25, 26].
Patients will also be asked to complete a diary of daily
activities as measure of physical activity by using a custom
designed diary modelled on a modified diary method of
Follick et al. [27, 28]. Participants will be asked to
complete this diary at least three times a day, recording
the activity undertaken for the majority of each 2-h block,
in addition to specifying whether oxygen cylinders were
used. In addition, total hours of outings each day will
be recorded.
Oxygen saturation
For 48 h during the second week of each treatment
period, patients will also be asked to wear a portable
oximeter to assess oxygen saturation for 48 continuous
hours. Measures of continuous oxygen saturation will
also allow control for self-reported use of ambulatory
oxygen.
At the end of each 2-week treatment period, the Sen-
seWear Armbands, the oximeters and the patient diaries
will be collected.
Assessment of compliance of oxygen cylinder use
Oxygen use will be expressed as number of full, half-full
and unused cylinders as self-reported by the patient after
each of the 2 weeks on oxygen. Patient-reported use will
be cross-checked by assessing accountability records
provided by the relevant oxygen company, following an
agreement that has been put in place.
To validate patient-reported use of oxygen cylinders, a
researcher at the Aintree site will sample 10 consecutive
patients living in the nearby area. The researcher will
visit patients at home at the end of the 2 weeks of ambu-
latory oxygen to independently assess numbers of fully
used, half-used and full oxygen cylinders. Comparison
between patient- and researcher-reported cylinders use
will be included in data analysis.
Patients will also be asked to fill in a daily oxygen use
diary card to write down the time of use of oxygen
canisters, and the activity being performed. This will be
cross-checked with the continuous oxygen saturation
data recorded by the portable oximeter, which patients
will be asked to wear for 2 days a week, so as to correlate
the two.
Qualitative assessments
The impact of using ambulatory oxygen will be identi-
fied through qualitative semistructured interviews with a
purposive sample of 20 patients. The interviews will ex-
plore patients’ and their informal carers’ perspectives on
how the ambulatory oxygen has affected their day to day
life. The interview will be conducted within 2 weeks of
the end of treatment visit. Patients from the RBH site
will be approached by a qualitative researcher at the end
of treatment visit and asked if they will participate in the
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qualitative interview (as described in the Patient Infor-
mation Sheet – Additional file 4). Consent of the patient
and carer will be confirmed before proceeding to the in-
terviews at a venue convenient to the patient.
The audio-recorded, semistructured interviews will
use a topic guide focussing on practical barriers to opti-
mal oxygen usage, practical, social and psychological dif-
ficulties encountered, concerns about dependency, and
views on the information required prior to ambulatory
oxygen prescription. The interviews will also explore pa-
tients’ experience of participating in the trial. Field notes
will be written after each interview to aid reflexive ana-
lytical processes [29]. These interviews will also allow
patients to provide suggestions on how to improve the
provision and future design of ambulatory oxygen
provision and devices as well as their views on the trial
design.
Safety assessments
Checking for the occurrence of adverse events and clin-
ical endpoints will begin from randomisation and will
continue until study completion. At each study visit the
investigator or designee will make an assessment of
safety and will specifically review the clinical history and
investigation findings with regard to the occurrence of
adverse events (AEs) or serious adverse events (SAEs).
Details of adverse and clinical events will be captured on
the trial electronic Case Report Form (eCRF).
Blood samples
Blood samples will be taken at the start of the 4-week
period to evaluate serum BNP levels. All BNP measure-
ments will be performed in the same laboratory at the
RBH.
Health economics
The AmbOx study will include an economic evaluation
to assess the cost-effectiveness of ambulatory oxygen use
in patients diagnosed with fibrotic ILD compared to no
ambulatory oxygen, from the perspective of the NHS. As
ambulatory oxygen is not anticipated to have any effect
on disease progression in the short term, costs related to
unplanned health professional appointments or hospital
admissions will not be included. The primary measure of
benefit for the economic evaluation will be change in K-
BILD score. Quality of life benefits will also be assessed
using quality-adjusted life years (QALYs). QALYs will be
estimated by synthesising utility values from existing
medical literature for health states described by the K-
BILD or SGRQ. Discounting will not be applied given
the short trial duration. Cost-effectiveness will be
expressed as the incremental cost per unit improvement
in K-BILD and per QALY gained.
We expect that ambulatory oxygen will allow patients
to lead an active and independent life for longer, with a
varied set of longer-term benefits, reducing the period of
dependency and expensive care packages associated with
the final stages of fibrotic ILD, characterised by severely
limited mobility. Therefore, future research should con-
sider modelling the longer-term costs and benefits of
ambulatory oxygen when sufficient data are available to
evidence this potential benefit. The economic evaluation
conducted alongside this trial will provide important
preliminary guidance on the likely cost-effectiveness of
implementing ambulatory oxygen in fibrotic ILD, as well
as evidence to support future studies that extrapolate
findings to a longer time horizon.
Discontinuation or withdrawal of study subjects
We do not expect there to be any significant toxicity
from the use of ambulatory oxygen. Subjects will be
withdrawn from the trial only if they wish to do so, or if
they develop an unexpected worsening in their condition
which means that they require oxygen at rest. Patients
withdrawing from the study will be asked, if willing and
whenever possible, to fill in the relevant questionnaires
at the end of the 2- and 4-week period, if needed via
telephone, so as to be able to compare change in health
status and other questionnaire-related outcomes, com-
pared to baseline, against subjects completing the trial.
Adverse event (AE) and serious adverse event (SAE)
reporting
AEs and SAEs will be identified according to standard
criteria and will be recorded in the eCRF and reported
to the sponsor. Given the nature of the participants’
underlying disease, expected AEs and SAEs include dis-
ease progression, lower respiratory tract infections, hos-
pitalisation, and death.
Data management and data checking
Data will be collected on an eCRF system. The InForm
system will be used to develop the eCRF and will be
designed in accordance with the requirements of the
clinical trial protocol and will comply with regulatory
requirements. Local personnel will be trained on the In-
Form system. Access will be restricted to site personnel,
trial managers, trial monitors and the data management
team. Personnel will have individual log-on and pass-
words. It will be the investigator’s responsibility to en-
sure the accuracy of all data entered and recorded in the
eCRFs. Trial monitors will check the accuracy of the
eCRF data against source documents. It is anticipated
that the majority of source data (medical progress notes
and letters, tests and investigations) will be filed in the
individual patients’ medical records. Any deviation from
source data being present in the medical notes will be
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identified and documented. The eCRF and source docu-
ments must be available at all times for review by the
sponsor’s clinical trial monitor, auditors and for inspec-
tion by the Medicines Health Regulatory Agency. The
accuracy of eCRF data will be verified by review of the
source documents and details will be provided in the
Trial Monitoring Report.
Statistical analysis
Before starting the data analysis, the level and pattern of
the missing data in the baseline variables and outcomes
will be established by forming appropriate tables. The
likely causes of any missing data will be investigated.
This information will be used to determine whether the
level and type of missing data have the potential to
introduce bias into the analysis results for the proposed
statistical methods, or to substantially reduce the preci-
sion of estimates related to treatment effects.
The potential effects of performance, attrition and
evaluation bias associated with the lack of a placebo arm
will be considered. Although we are not able to fully
exclude bias in the patient-reported outcomes, this will
be minimised by exploring correlations between the pri-
mary endpoint and secondary outcomes, including ana-
lysis of SenseWear Armband activity monitors, to assess
the possibility that a placebo effect is associated with
evaluation bias. Attrition bias should be minimised by
the fact that there will be no change in dosing for the
duration of the trial, and we do not expect there to be
any toxicity from the use of ambulatory oxygen. Subjects
will be withdrawn from the trial only if they wish to do
so or because of disease progression and the develop-
ment of hypoxia at rest. We do not expect there to be
any bias in the background provision of care (perform-
ance bias) depending on use or not of oxygen, as pa-
tients enrolled into the trial will be those not expected
to change their treatment for the duration of the study.
Although we will not adjust for baseline K-BILD
score in the primary analysis, secondary analyses using
the K-BILD filled in at baseline visit (week 0) as a co-
variate, or mean of the K-BILD score at screening visit
(week −2) and at baseline visit (week 0) will be
considered.
Primary outcome measure
 The primary outcome will be the difference in
K-BILD score on oxygen compared to no oxygen.
We will use a generalised linear model with the
difference in health status as the independent
variable and treatment sequence as a covariate.
If the assumption of the mixed model is not met,
data will be either log-transformed and/or other
nonparametric methods will be considered. Any
adjusted analyses will be performed as secondary
sensitivity analysis including adjusting for any
covariate that is itself linked to the primary outcome
(see below)
 Analysis of the primary outcome will be by intention-
to-treat. The data will be analysed according to the
initial randomisation groups irrespective of
subsequent withdrawals. However, should there
be a sizeable frequency of protocol variation,
per protocol analysis will also be performed
 The hypothesis to be tested is that ambulatory
oxygen improves health status compared to no
treatment. The study will be considered positive
if statistical significance at the level of 0.05
(two-tailed) is achieved
o Sensitivity analyses will include adjustment
for any covariates linked to the primary
outcome. These may include baseline K-BILD
measurement, age, gender, smoking history,
Body Mass Index (BMI), ILD severity as mea-
sured by the Composite Physiologic Index
(CPI), presence of PH as measured by echo,
baseline BNP levels, etc.
o Patient-reported consumption of oxygen
cylinders will also be factored in as a covariate.
Its validity will be checked against oxygen
company-reported cylinder consumption
wherever possible, and, in a subgroup of patients,
by direct observation by clinical nurse specialist
(CNS) home visits (Aintree centre)
o To assess the relationship between the response
to supplemental oxygen measured with a series
of parameters during the placebo air versus
oxygen 6MWT and the benefit seen in day-to-
day life with ambulatory oxygen, to identify
any baseline predictors of responsiveness. These
parameters will be included in the statistical
model as fixed- effect variables. Possible 6MWT
predictors to be analysed will include area under
the curve of oxygen saturation, walked distance,
maximum/minimum and mean heart rate,
end-test dyspnoea, end-test oxygen saturation,
end-test heart rate, and recovery times to
baseline dyspnoea, heart rate and saturation
o Exploratory sensitivity analyses of the effects
of ambulatory oxygen will be conducted in
predefined subgroups, including:
▪ IPF versus non-IPF
▪ Patients with and without evidence of PH
▪ Patients stopping and not stopping during the
baseline 6MWT on air
 STATA software will be used for statistical analysis
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Secondary outcomes
 Comparison of differences in secondary outcome
measures on and off ambulatory oxygen treatment,
will be performed by similar methods as for the
primary outcome
Qualitative interview analysis
Interviews will be transcribed verbatim, checked and
anonymised. Transcripts will be analysed thematically
using a framework approach [30]. NVivo 10 software
(QSR International Pty Ltd., www.qsrinternational.com)
will be used to manage and index the data prior to
charting, mapping and interpretation. Framework ana-
lysis provides a systematic approach to analysis useful
for applied qualitative research and enhances visibility of
analysis for policy-makers and practitioners. Further, it is
particularly useful for linking qualitative to quantitative
data. This would facilitate a mixed-methods analysis of
the broader dataset, thus providing comprehensiveness
and greater knowledge yield [31, 32], making best use of
the data collected.
Patient public involvement: patient/carer focus group
Patients and carers living with ILD who are not partici-
pating to the study will be invited to participate to a
focus group to provide patient and carer perspectives on
a sample of the anonymised interview transcripts and
their interpretation of the analysis.
Interim analyses
There will be no formal interim analysis as the study
duration is short, and we do not expect any significant
undesirable outcomes. A regular review of safety data
will be conducted to monitor the safety of patients in
the trial. A Data Monitoring Committee (DMC) will
follow number of deaths, early discontinuation due to
AEs and SAEs in an unblinded fashion. A planned DMC
meeting will be held to review all available data twice
yearly.
End of study
The final study visit will be the one at the end of the sec-
ond of the 2-week study periods The trial will formally
end when the final subject completes their week-4 visit.
Data from the study will be published in abstract form
at international meetings and will be submitted for pub-
lication in a peer-reviewed journal and will be reported
to the study funder.
Discussion
Fibrotic lung diseases are an important cause of morbid-
ity and mortality, with a devastating impact on quality of
life. With currently available treatments providing only
partial effectiveness and often, at best, stability of
disease, interventions to improve day-to-day quality of
life are crucial in this group of patients. This trial will be
the first to prospectively assess the impact of ambulatory
oxygen in patients with fibrotic ILD and to explore the
outcomes for which it is most effective, the predictors of
benefit and the variables/patient characteristics associ-
ated with lack of response. This study will form an
essential precursor to the development of ILD-specific
guidelines on ambulatory oxygen use. Ultimately, if
proven to be effective and cost-effective, the appropriate
prescription and use of ambulatory oxygen should lead
to prolonged patient independence and mobility, allow-
ing maintenance of fitness levels and of active roles in
daily life, with increased psychological and physical well-
being, as well as potentially reduced health-related costs.
Trial status
Recruitment to AmbOx began in August 2014. The trial
is currently actively recruiting in the UK.
Additional files
Additional file 1: AmbOx protocol v3.0. (PDF 440 kb)
Additional file 2: Figure S1. Flow diagram. (PPTX 269 kb)
Additional file 3: Patient Information Sheet: Version 3.0, 1 December 2014.
(DOC 337 kb)
Additional file 4: Informed Consent Form: Version 3.0, 1 December
2014. (DOC 32 kb)
Additional file 5: Exclusion criteria. (DOCX 15 kb)
Additional file 6: SPIRIT Checklist. (DOC 123 kb)
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